Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients

Trial Profile

Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2015

At a glance

  • Drugs BZF 961 (Primary) ; Ritonavir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 11 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Aug 2014 Planned End Date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 26 Aug 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top